Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Tygacil, Tigecycline. Every FDA application for this active ingredient: 4 branded and 5 generic.
As of Nov 15, 2026, FDA lists 9 applications for Tigecycline (sold as Tygacil, Tigecycline), first approved Jun 15, 2005, with 3 new uses approved and 0 published complete response letters.
First approved: Jun 15, 2005
Applications: 9
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $2.1M
First approved in the EU: Apr 24, 2006
First approved in Japan: Sep 28, 2012
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 87 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Tygacil, new ingredientA drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical… · Pfizer Japan Inc. · Sep 28, 2012
Clinical Trials
17 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sandoz
Fresenius Kabi USA
Accord Hlthcare Inc
Apotex
Eugia Pharma